Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 6/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 6/20 | 0.39 |
| ▸ | JAK3 | P52333 | 6/20 | 0.39 |
| ▸ | JAK1 | P23458 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17168775 | 0.85 | TYRO3 (0.41) | USP1TYRO3DYRK1BMTORMEN1 | |
| SCHEMBL4191400 | 0.84 | CYP1A2 (0.49) | USP1TYRO3DYRK1BMEN1LMNA | |
| SCHEMBL12067329 | 0.82 | USP1 (0.65) | USP1JAK2JAK3JAK1 | |
| SCHEMBL17807756 | 0.81 | USP1 (0.45) | USP1MTORPOLBJAK2JAK3 | |
| SCHEMBL15794948 | 0.81 | JAK2 (0.59) | USP1TYRO3DYRK1BJAK2JAK3 | |
| SCHEMBL15794950 | 0.81 | JAK2 (0.59) | USP1TYRO3DYRK1BJAK2JAK3 | |
| SCHEMBL15794946 | 0.79 | JAK2 (0.62) | USP1PGRJAK2JAK3JAK1 | |
| SCHEMBL15794947 | 0.79 | JAK2 (0.62) | USP1PGRJAK2JAK3JAK1 | |
| SCHEMBL23507970 | 0.79 | USP1 (0.41) | USP1MTORPOLBJAK2JAK3 | |
| SCHEMBL22419395 | 0.79 | USP1 (0.41) | USP1MTORPOLBJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
| EP-2212326-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009024824-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | USP1 1128/4885TYRO3 830/4885DYRK1B 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.